Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Size Of Drug Discounts In Part D Employer-Sponsored Plans At Stake In Debate Over CMS Proposal

Executive Summary

The biopharmaceutical industry is fighting a CMS proposal that would impact the size of manufacturer discounts on drugs provided in the Medicare Part D coverage gap in an emerging type of Part D coverage for retirees – employer-sponsored group waiver plans, known as EGWPs.

You may also be interested in...



PhRMA Urges Caution In Implementing Part D “Trial-Size” Prescriptions

The Pharmaceutical Research and Manufacturers of America, as well as pharmacy and PBM groups, recommend that CMS test its proposed policy to institute trial-size prescriptions before implementing it on a widespread basis to Medicare Part D.

Nursing Home Overprescribing: Pharmacist Independence Requirement Should Start As Demo, APhA Says

CMS’ proposal to reduce overprescribing in nursing homes draws cautiously favorable response from national pharmacist group, but long-term care pharmacy firm Omnicare argues the agency has not provided adequate justification for its plan.

Medicare Alzheimer’s Coverage Policy Advancing Clinical Trial Diversity Efforts

Medicare national coverage determination for Alzheimer’s drugs has been a ‘game changer’ in terms of motivating industry to boost diversity in clinical studies in the disease, trial expert says.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel